Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177849 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Faure Delgado Leon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Oncogene Proteins, Fusion, Molecular Targeted Therapy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Actionable ALK, ROS1, RET, NTRK, and NRG1 fusions define biologically distinct subsets of advanced non-small cell lung cancer (NSCLC), yet real-world data across these rare populations remain limited. We retrospectively evaluated patients with advanced NSCLC treated at Memorial Healthcare System who received genotype-matched fusion-directed therapy; the first fusion-directed agent defined the index treatment, and survival was measured from its initiation. Progression was determined from radiographic reports and treating-oncologist documentation. After patient-level reconciliation, 59 unique patients were included: 29 ALK, 14 ROS1, 11 RET, 3 NTRK, and 2 NRG1. Median follow-up was 47.7 months (95% CI, 28.6–58.7), median progression-free survival was 44.8 months (95% CI, 17.1–not estimable), and median overall survival was not reached. No statistically significant survival differences were detected among ALK, ROS1, and RET subgroups, although limited sample sizes preclude exclusion of clinically meaningful differences. Later-line index therapy was not significantly associated with progression-free survival in exploratory unadjusted analysis. These findings provide descriptive real-world evidence of precision-oncology implementation across actionable fusion-defined NSCLC while underscoring that pooled outcomes should not be interpreted as evidence of equivalent efficacy across molecular subtypes or therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Internal Medicine, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA.
- Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA.
- Oncology Research Department, Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33026, USA.
- Memorial Cancer Institute, Memorial Healthcare System, 703 N Flamingo Road, Pembroke Pines, FL 33028, USA.
ORCID-Profile: Maria Fernandez-Gomez, Luis Estuardo Raez
Zitieren
APA
Delgado Leon, F., de Armas, S. A., Molina, M., Morales, E. G., Fernandez-Gomez, M., & Raez, L. E. (2026). Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177849
Vancouver
Delgado Leon F, de Armas SA, Molina M, Morales EG, Fernandez-Gomez M, Raez LE. Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177849
BibTeX
@article{DelgadoLeon2026,
author = {Delgado Leon, Faure and de Armas, Suset Almuinas and Molina, Melanie and Morales, Eric G and Fernandez-Gomez, Maria and Raez, Luis Estuardo},
title = {Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177849}
}
EUVIMED